(VIANEWS) – Shares of PCI BIOTECH HOLD (Oslo Børs Benchmark Index_GI: PCIB.OL) fell by a staggering 11.5% to kr2.50 at 11:37 EST on Thursday, after three successive sessions in a row of gains. Oslo Børs Benchmark Index_GI is jumping 0.13% to kr1,239.63, following the last session’s downward trend. This seems, as yet, a somewhat positive trend exchanging session today.
PCI BIOTECH HOLD’s last close was kr2.83, 52.6% below its 52-week high of kr5.96.
About PCI BIOTECH HOLD
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.11.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.97%.
Moving Average
PCI BIOTECH HOLD’s worth is way above its 50-day moving average of kr1.94 and way above its 200-day moving average of kr2.09.
More news about PCI BIOTECH HOLD (PCIB.OL).
